Arcapta Neohaler (Novartis) is launched in USA for COPD

Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for chronic obstructive pulmonary disease by the FDA in July 2011. Indacaterol is already available in more than 30 countries following its first approval in the EU in November 2009 as Onbrez Breezhaler. The drug is approved in a total of 80 markets and further launches are due this year.